Therillume (“TLM” or the “Company”) is a clinical-stage neuro-oncology therapeutics company with an initial focus on glioblastoma (GBM) and Neurofibromatosis Type 1 and 2 (“NF1 and NF2”). Therillume is a human therapeutic spinout company from Recombinetics Inc. (“RCI”), leveraging its pioneering precise gene-editing platform to identify, validate and expedite high quality candidates through clinical development. In addition, Therillume is amassing a powerful consortium of KOL’s and leading institutions to advance novel and innovative therapies in neuro-oncology. The Company expects to enter the clinic in 2022 with therapies that have demonstrated safety and efficacy in human cancer clinical trials. Therillume is currently seeking Seed and Series A financing and strategic partners.
Company Details
- Employees
- 1
- Founded
- 2021
- Address
- 3388 Mike Collins Dr, Eagan,minnesota 55121,united States
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Keywords
- Oncology, Neurooncology, Therapeutic Development, Neurofibromatosis, Glioblastoma, Clinical Trials.
- HQ
- Eagan, Minnesota
Therillume Questions
Therillume's LinkedIn profile is https://www.linkedin.com/company/therillume
Therillume has
1 employees.
View email and phone details for 1
employees at Therillume.
Therillume's industry is
Pharmaceutical Manufacturing
Therillume's top competitors are
Us-Asia Technology Management Center,
Stemcells21,
Twin Cities Biotech,
All Before Dinner,
Surrogen,
Tess Research Foundation,
Ovagene Oncology,
Regenevida,
Lifengine Technologies,
Acceligen.
Therillume's categories are Pharmaceutical Manufacturing
Therillume's founding year is 2021
